Published in J Am Heart Assoc on May 27, 2015
Secondary Prevention of Small Subcortical Strokes Trial (SPS3) | NCT00059306
The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19. Expert Opin Drug Metab Toxicol (2015) 0.79
Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis. Eur J Clin Pharmacol (2016) 0.76
Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes). Stroke (2017) 0.75
A map of human genome variation from population-scale sequencing. Nature (2010) 121.13
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med (2012) 5.69
Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet (2013) 5.20
Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke (2001) 4.87
Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke (1995) 4.54
The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke (1988) 4.22
Incidence, 30-day case-fatality rate, and prognosis of stroke in Iquique, Chile: a 2-year community-based prospective study (PISCIS project). Lancet (2005) 4.15
Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther (2012) 4.05
Vascular cognitive impairment. Lancet Neurol (2003) 3.73
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol (2008) 3.10
Ischemic stroke subtypes : a population-based study of functional outcome, survival, and recurrence. Stroke (2000) 2.78
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther (2013) 2.73
Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost (2000) 2.45
The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke (2011) 2.35
The natural history of lacunar infarction: the Oxfordshire Community Stroke Project. Stroke (1987) 2.24
CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Stroke (2013) 2.12
The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther (2008) 2.04
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol (2010) 2.03
Incidence and case fatality rates of stroke subtypes in a multiethnic population: the South London Stroke Register. J Neurol Neurosurg Psychiatry (2002) 2.02
Clinical determinants of dementia related to stroke. Ann Neurol (1993) 1.58
Characterization of risk factors for vascular dementia: the Honolulu-Asia Aging Study. Neurology (1999) 1.44
Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J (2010) 1.25
Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. Am J Med Genet C Semin Med Genet (2014) 1.19
Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. Pharmacogenomics (2013) 1.14
Functional outcome in patients with lacunar infarction. Stroke (1996) 1.10
The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost (2012) 1.03
Clopidogrel pathway. Pharmacogenet Genomics (2010) 0.99
P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med (2003) 0.98
Stroke subtypes among Hispanics living in Guayaquil, Ecuador. Results from the Luis Vernaza Hospital Stroke Registry. Stroke (1993) 0.96
Intellectual impairment and cerebral lesions in multiple cerebral infarcts. A clinical-computed tomography study. Stroke (1988) 0.88
Reduced clopidogrel metabolism in a multiethnic population: prevalence and rates of recurrent cerebrovascular events. J Stroke Cerebrovasc Dis (2013) 0.82
Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel. Platelets (2014) 0.77
Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an updated meta-analysis. Thromb Res (2011) 0.77